Catalyst
Slingshot members are tracking this event:
Esperion (ESPR) Announces FDA Approval of NEXLETOL (bempedoic acid) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ESPR |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 21, 2020
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Nexletol, Bempedoic Acid
